The British Orthopaedic Oncology Management (BOOM) audit

dc.citation.epageBone Joint J. 2023 Oct 1;105-B(10):1115-1122. doi: 10.1302/0301-620X.105B10.BJJ-2023-0443.R1.
dc.citation.issue10
dc.citation.spage1115-1122
dc.citation.volume105-b
dc.contributor.authorArcher, J. E.
dc.contributor.authorChauhan, G. S.
dc.contributor.authorDewan, V.
dc.contributor.authorOsman, K.
dc.contributor.authorThomson, C.
dc.contributor.authorNandra, R. S.
dc.contributor.authorAshford, R. U.
dc.contributor.authorCool, P.
dc.contributor.authorStevenson, J.
dc.date.accessioned2024-02-01T13:19:24Z
dc.date.available2024-02-01T13:19:24Z
dc.date.epub2023-10-01
dc.date.issued2023-10-01
dc.description.abstractAIMS: Most patients with advanced malignancy suffer bone metastases, which pose a significant challenge to orthopaedic services and burden to the health economy. This study aimed to assess adherence to the British Orthopaedic Oncology Society (BOOS)/British Orthopaedic Association (BOA) guidelines on patients with metastatic bone disease (MBD) in the UK. METHODS: A prospective, multicentre, national collaborative audit was designed and delivered by a trainee-led collaborative group. Data were collected over three months (1 April 2021 to 30 June 2021) for all patients presenting with MBD. A data collection tool allowed investigators at each hospital to compare practice against guidelines. Data were collated and analyzed centrally to quantify compliance from 84 hospitals in the UK for a total of 1,137 patients who were eligible for inclusion. RESULTS: A total of 846 patients with pelvic and appendicular MBD were analyzed, after excluding those with only spinal metastatic disease. A designated MBD lead was not present in 39% of centres (33/84). Adequate radiographs were not performed in 19% of patients (160/846), and 29% (247/846) did not have an up-to-date CT of thorax, abdomen, and pelvis to stage their disease. Compliance was low obtaining an oncological opinion (69%; 584/846) and prognosis estimations (38%; 223/846). Surgery was performed in 38% of patients (319/846), with the rates of up-to-date radiological investigations and oncology input with prognosis below the expected standard. Of the 25% (215/846) presenting with a solitary metastasis, a tertiary opinion from a MBD centre and biopsy was sought in 60% (130/215). CONCLUSION: Current practice in the UK does not comply with national guidelines, especially regarding investigations prior to surgery and for patients with solitary metastases. This study highlights the need for investment and improvement in care. The recent publication of British Orthopaedic Association Standards for Trauma (BOAST) defines auditable standards to drive these improvements for this vulnerable patient group.
dc.description.admin-noteUnknown
dc.description.noteNot held
dc.identifier.citationArcher JE, Chauhan GS, Dewan V, Osman K, Thomson C, Nandra RS, et al. The British Orthopaedic Oncology Management (BOOM) audit. The bone & joint journal. 2023;105-b(10):1115-22.
dc.identifier.doi10.1302/0301-620x.105b10.Bjj-2023-0443.R1
dc.identifier.journalThe bone & joint journal
dc.identifier.pmid37777202
dc.identifier.urihttps://hdl.handle.net/11287/623159
dc.language.isoeng
dc.publisherBritish Editorial Society of Bone and Joint Journal
dc.relation.urlhttps://boneandjoint.org.uk/article/10.1302/0301-620X.105B10.BJJ-2023-0443.R1
dc.rights© 2023 The British Editorial Society of Bone & Joint Surgery.
dc.subjectHumans
dc.subjectOrthopedics
dc.subjectProspective Studies
dc.subjectRadiography
dc.subjectBone Neoplasms/surgery/secondary
dc.subjectThorax
dc.titleThe British Orthopaedic Oncology Management (BOOM) audit
dc.typeJournal Article
dc.type.versionepublish
Files